Electrophysiologic effects of carvedilol: Is carvedilol an antiarrhythmic agent?

PACE - Pacing and Clinical Electrophysiology

Volumn 28, Issue 9, 2005, Pages 985-990

  El Sherif, Nabil ^a   Turitto, Gioia ^a,b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b NEW YORK METHODIST HOSPITAL   (United States)

Author keywords

Arrhythmias; Carvedilol; Electrophysiology

Indexed keywords

ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR; ANTIARRHYTHMIC AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CARVEDILOL; CATALASE; DIGOXIN; ION CHANNEL; METOPROLOL; PROPRANOLOL; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; PROPANOLAMINE DERIVATIVE;

ANTIARRHYTHMIC ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROGENESIS; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; DRUG CLASSIFICATION; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ELECTROPHYSIOLOGY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEMODYNAMICS; HIGH RISK PATIENT; HUMAN; ION CURRENT; NONHUMAN; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; ACTION POTENTIAL; ANIMAL; HEART MUSCLE CONDUCTION SYSTEM;

ACTION POTENTIALS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTIOXIDANTS; ARRHYTHMIA; CARBAZOLES; HEART CONDUCTION SYSTEM; HUMANS; PROPANOLAMINES;

EID: 33644671765     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2005.00200.x     Document Type: Review

References (50)

1. Dunn CJ, Lea AP, Wagstaff AJ. Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 1997 54 : 161 185.
2. Cheng J, Kamiya K, Kodama I. Carvedilol: Molecular and cellular basis for its multifaceted therapeutic potential. Cardiovasc Drug Rev 2001 19 : 152 171.
3. Dulin B, Abraham WT. Pharmacology of carvedilol. Am J Cardiol 2004 93 (9A 3B 6B.
4. Feuerstein G, Shusterman NH, Ruffolo RR Jr. Carvedilol update IV. Prevention of oxidative stress, cardiac remodeling and progression of congestive heart failure. Drugs Today 1997 33 : 453 473.
5. Cheng J, Niwa R, Kamiya K, et al. Carvedilol blocks the repolarizing K+ currents and the L-type Ca++ current in rabbit ventricular myocytes. Eur J Pharmacol 1999 376 : 189 201.
6. Karle CA, Kreye VAW, Thomas D, et al. Antiarrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovasc Res 2001 49 : 361 370.
7. Brunvand H, Frlyland L, Hexeberg E, et al. Carvedilol improves function and reduces infarct size in the feline myocardium by protecting against lethal reperfusion injury. Eur J Pharmacol 1996 314 : 99 107.
8. Takusagawa M, Komori S, Matsumura K, et al. The inhibitory effects of carvedilol against arrhythmias induced by coronary reperfusion in anesthetized rats. J Cardiovasc Pharmacol Ther 2000 5 : 105 112.
9. Asanuma H, Minamino T, Sanada S, et al. Beta-adrenoceptor blocker carvedilol provides cardioprotection via an adenosine-dependent mechanism in ischemic canine heart. Circulation 2004 109 : 2273 2279.
10. Yue L, Melnyk P, Gaspo R, et al. Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ Res 1999 84 : 776 784.
11. Pu J, Boyden PA. Alterations of Na+ currents in myocytes from epicardial border of the infarcted heart. A possible ionic mechanism for reduced excitability and postrepolarization refractoriness. Circ Res 1997 81 : 110 119.
12. Maltsev VA, Sabbah HN, Undrovinas AI. Down-regulation of sodium current in chronic heart failure: Effect of long-term therapy with carvedilol. Cell Mol Life Sci 2002 59 : 1561 1568.
13. Yue L, Feng J, Gaspo R, et al. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997 81 : 512 525.
14. Nattel S, Danshi L. Ionic remodeling in the heart. Pathophysiological significance and new therapeutic opportunities for atrial fibrillation. Circ Res 2000 87 : 440 447.
15. Workman AJ, Kane KA, Russell JA, et al. Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: Evidence of pharmacological remodeling. Cardiovasc Res 2003 58 : 518 525.
16. Valenzuela C. Pharmacological electrical remodeling in human atria induced by chronic β-blockade. Cardiovasc Res 2003 58 : 498 500.
17. Wijffels MC, Kirchhoff CJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995 92 : 1954 1968.
18. Workman AJ, Kane KA, Rankin AC. The contribution of ionic currents to changes in refractoriness of human atrial myocytes associated with chronic atrial fibrillation. Cardiovasc Res 2001 52 : 226 235.
19. Van Wagoner DR, Pond AL, Lamorgese M, et al. Atrial L-type Ca++ currents and human atrial fibrillation. Circ Res 1999 85 : 428 436.
20. Brundel BJ, Hennings RH, Kampinga HH, et al. Molecular mechanisms of remodeling in human atrial fibrillation. Cardiovasc Res 2002 54 : 315 324.
21. Brundel BJ, Van Gelder JC, Hennings RH, et al. Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation. Circulation 2001 103 : 684 690.
22. Bosch RF, Zeng X, Grammer JB, et al. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res 1999 44 : 121 131.
23. Gaspo R, Bosch RF, Bou-Abboud E, et al. Tachycardia-induced changes in Na+ current in a chronic dog model of atrial fibrillation. Circ Res 1997 81 : 1045 1052.
24. Horio T, Ito S, Aoyama M, et al. Effect of carvedilol on atrioventricular conduction in the ischemic heart. Eur J Pharmacol 2001 412 : 145 153.
25. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996 334 : 1349 1355.
26. CAPRICORN Investigators. Effects of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: The CAPRICORN randomized trial. Lancet 2001 357 : 1385 1390.
27. Packer M, Fowler MB, Roecker EB, et al. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group: Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation 2002 106 : 2194 2199.
28. Poole-Wilson PA, Swedberg K, Cleland JGF, et al., for the COMET Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomized controlled trial. Lancet 2003 362 : 7 13.
29. Reiter MJ, Reiffel JA. Importance of beta-blockade in the therapy of serious ventricular arrhythmias. Am J Cardiol 1998 82 : 9I 19I.
30. Haverkamp W, Hindricks G, Gulker H. Antiarrhythmic properties of beta-blockers. J Cardiovasc Pharmacol 1990 16 (Suppl. 5 529 532.
31. Reiter MJ. B-adrenergic blocking drugs as antifibrillatory agents. Curr Cardiol Rep 2002 4 : 426 433.
32. Senior R, Muller-Beckmann B, DasGupta P, et al. Effects of carvedilol on ventricular arrhythmias. J Cardiovasc Pharmacol 1992 19 : S117 S121.
33. Cice G, Tagliamonte E, Ferrara L, et al. Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: Double-blind, randomized, placebo-controlled study. Eur Heart J 2000 21 : 1259 1264.
34. Remme WJ, Cleland JG, Di Lenarda A, et al. Consistent survival benefit of carvedilol over metoprolol irrespective of baseline characteristics of heart failure patients - mode of death evaluation in COMET abstract) J Card Fail 2004 10 : S84.
35. Piccirillo G, Quaglione R, Nocco M, et al. Effects of long-term beta-blocker (metoprolol or carvedilol) therapy on QT variability in subjects with chronic heart failure secondary to ischemic cardiomyopathy. Am J Cardiol 2002 90 : 1113 1117.
36. Fesmire SI, Marcoux LG, Lyyski DS, et al. Effects of selective versus nonselective beta blockade on QT dispersion in patients with nonischemic dilated cardiomyopathy. Am J Cardiol 1999 84 : 350 354.
37. Barr CS, Freeman M, Lang CC, et al. QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994 343 : 327 329.
38. Meng F, Yoshikawa T, Baba A, et al. Beta-blockers are effective in congestive heart failure patients with atrial fibrillation. J Card Fail 2003 9 : 398 403.
39. Gheorghiade M, Lukas MA. Role of carvedilol in atrial fibrillation: Insights from clinical trials. Am J Cardiol 2004 93 (9A 53B 57B.
40. Joglar JA, Acusta AP, Shusterman NH, et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: Retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J 2001 142 : 498 501.
41. Khand AU, Rankin AC, Martin W, et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 2003 42 : 1944 1951.
42. Katsiris DG, Panagiotakos DB, Karvouni E, et al. Comparison of the effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. Am J Cardiol 2003 92 : 1116 1119.
43. Kanoupakis EM, Manios EG, Mavrakis HE, et al. Comparative effects of carvedilol and amiodarone on conversion and recurrence rates of persistent atrial fibrillation. Am J Cardiol 2004 94 : 659 662.
44. Merritt JC, Niebauer M, Tarakji K, et al. Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation. Am J Cardiol 2003 92 : 735 736.
45. Mihm MJ, Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001 104 : 174 180.
46. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias. Circulation 2001 104 : 2886 2891.
47. Carnes CA, Chung MK, Nakayama T, et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 2001 89 : E32 E38.
48. McMurray J, Kober L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction. Results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) Trial. J Am Coll Cardiol 2005 45 : 525 530.
49. Pratt CM. Three decades of clinical trials with beta-blockers. The contribution of the CAPRICORN Trial and the effect of carvedilol on serious arrhythmias. J Am Coll Cardiol 2005 45 : 531 532.
50. Hallstrom A, Pratt CM, Greene HL, et al. The interrelationships between heart failure, ejection fraction, arrhythmia suppression and mortality: Analysis of the Cardiac Arrhythmia Suppression Trial (CAST). J Am Coll Cardiol 1995 25 : 1250 1257.